DER PERFEKTE URLAUB

Alte Freunde, neue Geheimnisse und jede Menge Malle!

Plakat und Trailer ab sofort online!

München (ots)

Reif für den Urlaub mit den besten Freunden und bereit für die nächste Eskalationsrunde? Dann nichts wie los und schon einmal den neuen Trailer von DER PERFEKTE URLAUB klicken: Link zum Trailer

Das Star-Ensemble ist zurück! Nach DAS PERFEKTE GEHEIMNIS kommt DER PERFEKTE URLAUB. Aber wer traut nach dem Handy-Spiel eigentlich noch wem? Ein Kurztrip der Clique endet unfreiwillig in einem spanischen Ferienclub. Doch der perfekte Urlaub eskaliert.

Nach dem Kinohit DAS PERFEKTE GEHEIMNIS mit mehr als 5,3 Mio. verkauften Kinotickets versammeln die Filmemacher*innen Bora Dagtekin und Lena Schömann auch in DER PERFEKTE URLAUB einen prominenten Cast vor der Kamera: Erneut zählen Elyas M'Barek, Karoline Herfurth, Jessica Schwarz, Florian David Fitz, Jella Haase, Frederick Lau, Wotan Wilke Möhring sowie Emily Kusche zum bewährten Ensemble, das Unterstützung von Diana Amft als Carlottas (Karoline Herfurth) beste Freundin erhält. In weiteren Rollen sind David Korbmann, Maria Dragus, Daniel Zillmann, Caroline Maria Frier, Inez Bjørg David und Jan van Weyde ab dem 22. Oktober im Verleih der Constantin Film im Kino zu sehen.

Zum Inhalt:

Mehr als fünf Millionen Deutsche reisen jedes Jahr nach Mallorca. Leo (Elyas M'Barek), Pepe (Florian David Fitz), Rocco (Wotan Wilke Möhring) und Simon (Frederick Lau) nehmen sich ebenfalls eine Auszeit im 17. Bundesland. Erst mal Wunden lecken, sich sammeln, Abstand gewinnen. Seit dem entgleisten Handy-Spiel ist nichts mehr, wie es war. Guter Plan. Blöd nur, dass aus dem entspannten Jungs-Trip nichts wird: Eva (Jessica Schwarz), Carlotta (Karoline Herfurth) und ihre beste Freundin Maus (Diana Amft) haben sich in derselben Villa auf Malle einquartiert. Auf die harte Tour muss die dysfunktionale Clique herausfinden, was von Freundschaft, Vertrauen und Liebe überhaupt noch übrig ist. Und als die Finca in Flammen aufgeht und die Freunde in einem Gute-Laune-Clubhotel stranden, bringen alte Wunden und neue Enthüllungen die Fassaden endgültig zum Bröckeln. Bald steht nicht nur jede einzelne Beziehung, sondern die gesamte Freundschaft auf dem Spiel. Kann Leo nach seiner SMS-Affäre Carlottas Vertrauen zurückgewinnen? Eva hat nicht nur Stress mit ihrer Teenager-Tochter Sophie (Emily Kusche), sondern auch mit ihrem Mann. Beide ahnen, dass sie sich gegenseitig etwas verschweigen, doch mit Roccos Zweithandy hatte Eva nicht gerechnet. Pepe, frisch geoutet, wünscht sich mehr Support von seinen Hetero-Kumpels, während er sich selbst noch nicht ganz gefunden hat. Und Simon ist der Charmeur geblieben, der jede Konsequenz wegwitzelt. Doch als seine Ex-Freundin Bianca (Jella Haase) auftaucht, geht es ans Eingemachte ... VAMOS A LA DRAMA!

DER PERFEKTE URLAUB ist eine Constantin Film Produktion und wurde mit Mitteln des FilmFernsehFonds Bayern (FFF), der Filmförderanstalt (FFA) und des Deutschen Filmförderfonds (DFFF) gefördert. Der Film erhielt das Green Motion Label. Das Drehbuch stammt von Bora Dagtekin, der auch Regie führte. Produzentin ist Lena Schömann, Producerin Nicole Springstubbe. Executive Producer ist Oliver Berben.

Kinostart: 22. Oktober 2026 im Verleih der Constantin Film

Darsteller*innen: Elyas M'Barek, Karoline Herfurth, Jessica Schwarz, Florian David Fitz, Jella Haase, Frederick Lau, Diana Amft, Wotan Wilke Möhring, Emily Kusche, David Korbmann, Paul Ahrens, Maria Dragus, Daniel Zillmann, Caroline Maria Frier, Jan van Weyde, Inez Bjørg David u.v.m.

Drehbuch & Regie: Bora Dagtekin

Produzentin: Lena Schömann

Producerin: Nicole Springstubbe

Executive Producer: Oliver Berben

Erstes Pressematerial zum Film steht unter https://presse.constantin.film zum Download zur Verfügung.

Wenn Sie weitere Informationen wünschen, wenden Sie sich bitte an die betreuende Agentur:

Pressekontakt:

JUST PUBLICITY GmbH

(TV-, Print-, Hörfunk-PR)

Regine Baschny, Sabrina Wintersberger & Saskia Wach

Tel. 089 20 20 82 60

info@just-publicity.com

JUST PUBLICITY ONLINE GmbH

(Online PR)

Nina Schattkowsky & Mona Seybold

Tel. 030 5093134 20

info@just-publicity-online.com

Original-Content von: Constantin Film, übermittelt durch news aktuell

TwinDEX Introduces a Scalable Path from Robot-Free Data Collection to Real-World Dexterous Manipulation

SHENZHEN, China, Sept. 2, 2026 /PRNewswire/ -- Today, X Square Robot introduced TwinDEX, a pair of co-designed, three-finger, nine-DoF dexterous manipulation interface: one wearable for data collection, one for robot deployment. Together with synchronized sensing, a data processing pipeline, and a policy training workflow, the manipulation interface creates a direct and scalable path from robot-free data collection to real-world dexterous manipulation.

The data problem behind dexterous manipulation

Robots operating in open environments must do much more than pick and place objects. They need to twist, insert, pour, open latches, use tools, handle narrow spaces, and adjust through contact. These tasks depend not only on where the hand moves, but also on how the fingers make contact, when force is applied, and how the system corrects small errors in a closed loop.

Training data remains a major bottleneck. On-robot teleoperation produces demonstrations that match the target hardware, but it is expensive and difficult to scale: Teleoperation occupies the robot, requires a prepared workspace, and often depends on a skilled operator. Robot-free collection is easier to scale, but it can create an embodiment gap. If the collection device and the robot differ in kinematics, fingertip geometry, visual appearance, or timing, a demonstration may lose contact relationships that made the original action successful.

TwinDEX is designed to narrow this gap through the co-design of its data-collection and deployment hardware. It pairs a wearable data-collection device with a closely matched robotic end effector. Both share a three-finger, nine-degree-of-freedom architecture, comprising seven active and two passive degrees of freedom.

The design is built around three principles:

Dexterity. The three-finger configuration supports stable power grasps, precise pinches, multi-point contact, twisting, and tool usage. The team evaluated different hardware configurations using a benchmark covering several manipulation primitives. Within the current task set, seven active degrees of freedom provided the best balance among dexterity, mechanical complexity, cost, wearability, and reliability.

Consistency. The collection and deployment devices are aligned across the parts of the system that affect policy learning. They share corresponding kinematic chains, joint axes, link proportions, contact geometry, surface materials, visual appearance, and sensor placement. This allows measured finger states to map directly to the robot joint space without complex hand-to-robot retargeting.

Consistency also includes data accuracy and time. TwinDEX synchronizes multi-view RGB camera inputs, six-degree-of-freedom wrist poses, finger joint states, and fingertip tactile signals. The team measures delays across sensing, inference, and execution so that the observation-action relationship seen during training better matches the one experienced during deployment.

Scalability. An operator can wear the exoskeleton and interact directly with real objects, without using a robot during data collection. One operator, one table, and one wearable system form a complete collection unit. This makes it possible to collect in offices, kitchens, workstations, and other real environments, while multiple operators can collect in parallel at different locations.

Direct interaction also preserves the operator's natural visual, contact, and proprioceptive feedback. This is especially useful for contact-rich tasks that are difficult to demonstrate through conventional teleoperation, where latency, limited viewpoints, and indirect force feedback can slow the operator or introduce unnatural motion.

Demonstrating long-horizon, contact-rich behavior

TwinDEX was evaluated on everyday manipulation tasks including cap twisting, sweeping with a broom and dustpan, sliding out and opening a book, releasing toolbox latches, and operating a syringe. These tasks test precise contact, tool control, small-target alignment, grasp transitions, and bimanual coordination. In the collection evaluation, TwinDEX delivered up to 5.3 times the effective throughput of on-robot teleoperation.

The system was then tested on a full standardized chemistry experiment executed autonomously in a single uncut run. Across 24 sub-actions, the robot had to open and stabilize containers, handle a thin scooper, use a rubber-bulb pipette, transfer liquids and solids, hold a nearly transparent glass rod against a beaker, guide a pour, switch tools, and coordinate both hands. Each stage required precise positioning and stable control through contact.

The chemistry demonstration shows that, when wearable collection and robotic deployment systems are closely aligned, a policy can learn fine-grained, long-horizon dexterous behavior from only a few hundred robot-free episodes, without any on-robot training data.

When data is no longer locked behind expensive robot hardware, when every demonstration is natively aligned with the target end effector, and when hardware, data, and models evolve together around the same closed loop, dexterous manipulation data can finally scale by orders of magnitude. TwinDEX is building exactly that path: one that can be replicated, measured, and continuously improved.

Project link: https://x2robot.com/en/pages/twindex

For more information, visit https://x2robot.com/

About X Square Robot

X Square Robot focuses on developing its own general-purpose embodied AI models and robotic hardware. As a leading Chinese company in the field, it has pioneered the deployment of general-purpose embodied AI in real-world settings such as homes and logistics.

SOURCE X Square Robot

Share this article

SAN ANTONIO, Sept. 2, 2026 /PRNewswire/ -- Operation Homefront® is proud to announce that nominations are now open for the 19th annual Military Child of the Year® Award, its signature program recognizing the resilience, leadership, and achievements of America's military children.

Each year, this prestigious award recognizes seven outstanding young individuals, one from each branch of the armed forces — Army, Marine Corps, Navy, Air Force, Space Force, Coast Guard, and National Guard. Eligible nominees must be between 13 and 18 years old, be legal dependents of a service member or military retiree, and demonstrate a commitment to excellence in areas such as academics, civic leadership, volunteerism, athletics, and the arts. Nominations will be accepted through December 1, 2026.

Behind every military family's service and sacrifice are children who regularly adjust to new communities, schools, and circumstances while continuing to thrive and give back. The Operation Homefront Military Child of the Year Award celebrates those who have made a meaningful impact through their contributions, determination, and involvement in their schools and communities despite these challenges. The 2026 recipients exemplify the caliber of young people recognized through this program. Collectively, the seven award recipients contributed more than 4,800 volunteer hours in the year leading up to their nominations and experienced a combined 35 military moves. Their achievements and commitment to others embody the tenacious spirit of the military community.

"Each of our nation's 1.6 million military children carries a story of strength, sacrifice, and service that deserves to be recognized," said retired Rear Adm. Alan Reyes, President and CEO of Operation Homefront. "Having experienced military life as a child and having raised two daughters in a military family, I understand the challenges and uncertainty these young people often face through circumstances beyond their control. Serving quietly behind the scenes, they demonstrate leadership, perseverance, and character well beyond their years. Their actions, accomplishments, and support for others make a lasting difference wherever military life takes them. The Operation Homefront Military Child of the Year Award shines a spotlight on their journeys and the contributions they make along the way."

All seven Operation Homefront Military Child of the Year Award recipients will be invited to attend the Military Child of the Year Awards Gala in April 2027 in Arlington, VA, where they will each receive $10,000, a laptop, and additional gifts from Operation Homefront's generous corporate partners.

Operation Homefront will provide airfare and lodging for each award recipient and two family members to attend the gala and spend a few days in the Washington, D.C. area.

Previous recipients have had the opportunity to meet Chairmen of the Joint Chiefs of Staff and their spouses, First Lady Michelle Obama, acclaimed broadcaster Lindsay Czarniak, and other distinguished leaders, celebrities, and philanthropists who have participated as guest speakers and entertainers.

"It felt meaningful being named Military Child of the Year, not just for the challenges I've faced as a military child, but for everything I've accomplished because of them. So much of my childhood happened behind the scenes, the hard mornings without my parents home, constant moves, deployments, and responsibilities that most kids never have to think about. Being acknowledged for those experiences makes me feel understood in a way that is rare. But what means even more is being recognized for the person I've become because of them – resilient, adaptable, responsible, and driven," said Victoria V., 2026 Military Child of the Year representing Coast Guard.

Anyone can nominate a military child—from family members and friends, to teachers, coaches, counselors, and clergy. Everyone is encouraged to recognize the outstanding military children in their lives. Visit operationhomefront.org/military-child-of-the-year to learn more and nominate a child for their respective branch award.

About Operation Homefront: Operation Homefront is a national nonprofit organization whose mission is to build strong, stable, and secure military and veteran families by improving their financial, emotional and social well-being. Recognized for superior performance by leading independent charity oversight groups, 85 percent of Operation Homefront expenditures go directly to programs that support tens of thousands of military families each year. Operation Homefront provides critical financial assistance, transitional and permanent housing, and family support services to prevent short-term needs from turning into chronic, long-term struggles. Thanks to the generosity of our donors and the support from thousands of volunteers, Operation Homefront proudly serves America's military families. For more information, visit OperationHomefront.org.

SOURCE Operation Homefront

Share this article

-NovaGo Therapeutics cierra una ronda de financiación Serie B de 30 millones de dólares para impulsar un estudio de prueba de concepto en lesiones agudas de la médula espinal

La ronda fue liderada por Neurimmune y Pureos, con la participación de inversores actuales y nuevos; complementada con financiación no dilutiva de la Fundación Suiza para Parapléjicos y Wings for Life - Fundación para la Investigación de la Médula Espinal.

SCHLIEREN, Suiza, 2 de septiembre de 2026 /PRNewswire/ -- NovaGo Therapeutics AG, una empresa de biotecnología en fase clínica que desarrolla fármacos biológicos anti-Nogo-A para enfermedades del sistema nervioso central, anunció hoy la finalización exitosa de una ronda de financiación Serie B de 24 millones de francos suizos (30 millones de dólares estadounidenses). La ronda fue liderada por Neurimmune y Pureos, con la participación de inversores actuales y nuevos. La financiación mediante capital se complementa con fondos no dilutivos de la Fundación Suiza para Parapléjicos y Wings for Life.

Los fondos obtenidos se utilizarán para impulsar el programa principal de NovaGo hacia un estudio de prueba de concepto (PoC) en pacientes con lesión medular aguda. El estudio es un ensayo completamente aleatorizado y doble ciego que recluta a 120 pacientes en centros de Alemania, España y Suiza.

La lesión medular sigue siendo un área con una gran necesidad médica no cubierta. Actualmente no existen opciones de tratamiento regenerativo aprobadas que restauren la función neurológica perdida, lo que deja a los pacientes y sus familias con perspectivas terapéuticas limitadas tras la lesión. El enfoque de NovaGo se centra en Nogo-A, una proteína que inhibe la regeneración de las fibras nerviosas y la neuroplasticidad en el sistema nervioso central, con el objetivo de permitir la recuperación funcional.

"Nos entusiasma ver que este programa avanza hacia esta etapa crucial de los ensayos clínicos, lo que nos acerca un paso significativo a un tratamiento muy necesario para los pacientes que viven con las consecuencias de una lesión medular", declaró el profesor Martin Schwab, director científico de NovaGo Therapeutics.

"Junto con NovaGo Therapeutics, estamos siendo pioneros en un enfoque innovador para el tratamiento de la lesión medular mediante un anticuerpo terapéutico totalmente humano diseñado para promover la regeneración nerviosa tras la lesión", declaró el profesor Roger M. Nitsch, presidente y consejero delegado de Neurimmune y miembro del Consejo de Administración de NovaGo Therapeutics. "Nos alientan los prometedores resultados de la Fase 1 con NG004 y esperamos avanzar en el programa de desarrollo clínico junto con NovaGo Therapeutics y nuestros coinversores, con el generoso apoyo de la Fundación Suiza para Parapléjicos y Wings for Life".

"Nos complace enormemente coliderar esta financiación y apoyar la siguiente etapa de desarrollo de NovaGo. El progreso y los resultados del estudio de Fase 1 en lesión medular son muy alentadores y vemos un gran potencial para ofrecer una nueva opción de tratamiento regenerativo para pacientes con lesión medular", afirmó Dominik Escher, socio gerente de Pureos Bioventures.

"Estamos profundamente agradecidos por el respaldo de nuestros inversores. El apoyo de Wings for Life y la Fundación Suiza para Parapléjicos también ha sido fundamental, haciendo posible esta crucial fase de desarrollo", declaró Stefan Moese, consejero delegado de NovaGo Therapeutics. "Su compromiso nos permite avanzar con el estudio de prueba de concepto y trabajar para ofrecer un tratamiento muy necesario a los pacientes afectados por las devastadoras consecuencias de las lesiones de la médula espinal".

Acerca de Pureos Bioventures

Pureos Bioventures es un fondo de capital de riesgo asesorado por la firma suiza de capital de riesgo Pureos Partners. Invierte exclusivamente en empresas privadas innovadoras de desarrollo de fármacos, con especial énfasis en la próxima generación de fármacos biológicos y formatos de medicamentos. Las empresas de la cartera del fondo se basan en la excelencia científica para desarrollar terapias en un amplio espectro de indicaciones, que incluye oncología, inmunología, oftalmología, enfermedades raras y neurociencia. Pureos ha formado un equipo con amplia experiencia en inversión, operaciones y clínica, que se esfuerza por mejorar la vida de los pacientes mediante el avance de tratamientos innovadores para enfermedades devastadoras. Para obtener más información, visite www.pureosbio.com.

Acerca de Neurimmune

Neurimmune es una empresa biofarmacéutica en fase clínica que desarrolla terapias con anticuerpos de última generación. La empresa es pionera en la eliminación de amiloide como un novedoso mecanismo terapéutico para tratar enfermedades del SNC y enfermedades relacionadas con la agregación de proteínas, como la enfermedad de Alzheimer, la esclerosis lateral amiotrófica y la cardiomiopatía por ATTR. Neurimmune descubrió el anticuerpo anti-ATTR cliramitug (anteriormente NI006, ALXN2220, Fase 3) para la cardiomiopatía por ATTR, el anticuerpo anti-SOD1 mal plegado AP-101 (Fase 2) para la ELA, el anticuerpo anti-Nogo-A NG004 (Fase 1) para la lesión de la médula espinal y el anticuerpo de cadena ligera anti-amiloide NI009 (preclínico) para la amiloidosis AL.

Acerca de NovaGo Therapeutics

NovaGo Therapeutics AG es una empresa de biotecnología en fase clínica que desarrolla nuevos fármacos biológicos anti-Nogo-A para promover la regeneración nerviosa y la recuperación funcional en pacientes con enfermedades y lesiones del sistema nervioso central, como lesiones de la médula espinal, accidentes cerebrovasculares y esclerosis múltiple progresiva secundaria. Fundada a partir de una investigación pionera sobre Nogo-A como inhibidor clave de la regeneración neuronal, NovaGo está impulsando su principal candidato a través del desarrollo clínico con el objetivo de ofrecer el primer tratamiento regenerativo para pacientes con lesión aguda de la médula espinal. NovaGo tiene su sede en Suiza.

Para más información, póngase en contacto con:

NovaGo Therapeutics AG

media@novagotx.com

www.novagotherapeutics.com 

Share this article

Round led by Neurimmune and Pureos, with participation from existing and new investors; complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life - Spinal Cord Research Foundation.

SCHLIEREN, Switzerland, Sept. 2, 2026 /PRNewswire/ -- NovaGo Therapeutics AG, a clinical-stage biotechnology company developing anti-Nogo-A biologics for diseases of the central nervous system, today announced the successful completion of a CHF 24 million (USD 30 million) Series B financing round. The round was led by Neurimmune and Pureos, with participation from existing and new investors. The equity financing is complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.

Proceeds from the financing will be used to advance NovaGo's lead program into a proof-of-concept (PoC) study in patients with acute spinal cord injury. The study is a fully randomized, double-blind trial enrolling 120 patients across sites in Germany, Spain, and Switzerland.

Spinal cord injury remains an area of high unmet medical need. There are currently no approved regenerative treatment options that restore lost neurological function, leaving patients and their families with limited therapeutic prospects following injury. NovaGo's approach targets Nogo-A, a protein that inhibits nerve fiber regeneration and neuroplasticity in the central nervous system, with the goal of enabling functional recovery.

"We are excited to see this program progress into this critical stage of clinical testing, bringing us a meaningful step closer to a much-needed treatment for patients living with the consequences of spinal cord injury," said Prof. Martin Schwab, Chief Scientific Officer of NovaGo Therapeutics.

"Together with NovaGo Therapeutics, we are pioneering a novel approach for the treatment of spinal cord injury using a fully human therapeutic antibody designed to promote nerve outgrowth after injury," said Prof. Roger M. Nitsch, President and Chief Executive Officer of Neurimmune and a member of the Board of Directors of NovaGo Therapeutics. "We are encouraged by the promising Phase 1 results with NG004 and look forward to advancing the clinical development program together with NovaGo Therapeutics and our co-investors, with generous support from the Swiss Paraplegic Foundation and Wings for Life."

"We are very pleased to co-lead this financing and support NovaGo's next stage of development. The progress and results from the Phase 1 study in spinal cord injury are very encouraging and we see great potential to provide a new regenerative treatment option for patients with spinal cord injury," said Dominik Escher, Managing Partner at Pureos Bioventures.

"We are deeply grateful for the backing of our investors. Support from Wings for Life and the Swiss Paraplegic Foundation have also been instrumental, helping make this crucial development phase possible." said Stefan Moese, Chief Executive Officer of NovaGo Therapeutics. "Their commitment allows us to move forward with the proof-of-concept study and work toward bringing a much-needed treatment to patients affected by the devastating consequences of spinal cord injury."

About Pureos Bioventures

Pureos Bioventures is a venture fund advised by the Swiss venture capital firm Pureos Partners. It invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund's portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients' lives by advancing innovative treatments for devastating diseases. For more information, please visit www.pureosbio.com.

About Neurimmune

Neurimmune is a clinical-stage biopharmaceutical company building next-generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer's disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. Neurimmune discovered the anti-ATTR antibody cliramitug (formerly NI006, ALXN2220, Phase 3) for ATTR cardiomyopathy, the anti-misfolded SOD1 antibody AP-101 (Phase 2) for ALS, the anti-Nogo-A antibody NG004 (Phase 1) for spinal cord injury, and the anti-amyloid light chain antibody NI009 (preclinical) for AL amyloidosis.

About NovaGo Therapeutics

NovaGo Therapeutics AG is a clinical-stage biotechnology company developing novel anti-Nogo-A biologics to promote nerve regeneration and functional recovery in patients with diseases and injuries of the central nervous system, including spinal cord injury, stroke, and secondary progressive multiple sclerosis. Founded on pioneering research into Nogo-A as a key inhibitor of neuronal regeneration, NovaGo is advancing its lead candidate through clinical development with the goal of delivering the first regenerative treatment for patients with acute spinal cord injury. NovaGo is based in Switzerland.

For more information, please contact:

NovaGo Therapeutics AG

media@novagotx.com

www.novagotherapeutics.com 

SOURCE NovaGo Therapeutics

Share this article

EVB ultra-slim 150 kW DC EV charger wins 2026 iF and Red Dot design awards

WENZHOU, China, Sept. 2, 2026 /PRNewswire/ -- EVB, a provider of electric vehicle charging infrastructure and solutions, announced that its BUDC ultra-slim dual-connector DC EV charger has received the iF DESIGN AWARD 2026 and the Red Dot Award: Product Design 2026. The recognitions highlight the product's combination of industrial design, engineering performance and deployment value.

With a total output of 150 kW and a body thickness of approximately 100 mm, the BUDC addresses a common challenge for European DC fast-charging projects: installing high-power equipment where space is limited. Its flat architecture supports wall-mounted and embedded installation in urban streets, parking facilities, bus depots, truck depots and fleet sites.

The BUDC can be configured with dual CCS2 connectors and features an IP65-rated enclosure for outdoor installations. A single connector can deliver up to 150 kW, while intelligent power allocation distributes available output when two vehicles charge simultaneously. Its liquid-cooling system and independently replaceable AC, DC and control modules simplify maintenance and support reliable operation.

"Winning both the iF DESIGN AWARD and the Red Dot Award confirms that charging infrastructure can deliver strong performance without compromising the spaces in which it is installed," said Jundan Wang, CEO of EVB. "The BUDC was developed to help charge point operators and fleet customers use limited space more efficiently while providing a reliable and intuitive charging experience."

EVB's DC EV charging solutions form part of a broader portfolio ranging from 3.7 kW AC chargers to 2,000 kW megawatt charging systems. Across its European portfolio, EVB offers models and configurations with CE marking and TÜV certification, as well as support for OCPP 1.6J/2.0.1 and ISO 15118 Plug & Charge. Depending on the selected model and project configuration, EVB can also provide MID-compliant metering, credit or debit card payments, and contactless payment options for European charge point operators (CPOs) and public charging networks.

About EVB

EVB is an EV charging infrastructure provider and a subsidiary of BENY New Energy, a renewable energy company established in 2011. With China-based manufacturing and an office in Germany, EVB supports partners and projects across Eastern, Southeastern, Western and Southern Europe. The company has completed more than 25,000 projects across more than 100 countries and regions.

Media Contact

Wayne Li

Marketing Manager

Email: info@evb.com

Tel: +86 17607988287

BUDC

https://www.evb.com/product-item/dc-ultra-thin-dual-gun-charger-150kw/ 

DC EV charging solutions

https://www.evb.com/by-charging-type/evb-dc-ev-charging-solutions/ 

EVB 

https://www.evb.com/corporate-profile/ 

BENY New Energy

https://www.beny.com/ 

Share this article

Trip.com Group Limited to Report Second Quarter and First Half of 2026 Financial Results on September 15, 2026 U.S. Time

SINGAPORE, Sept. 2, 2026 /PRNewswire/ -- Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961), a leading one-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours and corporate travel management, will announce its financial results for the three months and six months ended June 30, 2026 on Tuesday, September 15, 2026, U.S. Time, after the market closes.

Trip.com Group's management team will host a conference call at 8:00 PM U.S. Eastern Time on September 15, 2026 (or 8:00 AM on September 16, 2026 in the Hong Kong Time) following the announcement.

The conference call will be available on Webcast live and replay at: http://investors.trip.com. The call will be archived for twelve months at this website.

All participants must pre-register to join this conference call using the Participant Registration link below:

https://register-conf.media-server.com/register/BI2674f539340943acacf4a39cf6d51444.

Upon registration, each participant will receive details for this conference call, including dial-in numbers and a unique access PIN. To join the conference, please dial the number provided, enter your PIN, and you will join the conference instantly.

About Trip.com Group Limited

Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961) is a leading global one-stop travel platform, integrating a comprehensive suite of travel products and services and differentiated travel content. It is the go-to destination for many travelers in Asia, and increasingly for travelers around the world, to explore travel, get inspired, make informed and cost-effective travel bookings, enjoy hassle-free on-the-go support, and share travel experience. Founded in 1999 and listed on Nasdaq in 2003 and HKEX in 2021, the Company currently operates under a portfolio of brands, including Ctrip, Qunar, Trip.com and Skyscanner, with the mission "to pursue the perfect trip for a better world."

For further information, please contact:

Investor Relations

Trip.com Group Limited

Email: iremail@trip.com

SOURCE Trip.com Group Limited

Share this article

PROVIDENCIALES, Turks and Caicos Islands, Sept. 2, 2026 /PRNewswire/ -- KuCoin Web3 Wallet today announced an upgrade to its wallet-native trading infrastructure, bringing intent-based swaps and limit orders into a unified self-custodial interface. Through integrations with UniswapX, PancakeSwapX and 1inch, the update gives users more flexible ways to trade supported crypto assets and tokenized real-world assets directly within the wallet.

Web3 wallets are evolving beyond asset storage into a unified access point for discovering, interacting with, and trading onchain markets. As this shift accelerates, the user experience increasingly depends not only on market access, but also on how efficiently orders are routed and executed. The latest upgrade strengthens this execution layer while reducing the need to navigate multiple DApps and disconnected trading workflows.

Through UniswapX and PancakeSwapX, eligible swaps can access intent-based execution, where users specify the desired transaction outcome and third-party fillers or solvers compete to execute the order. Depending on the supported asset, network and available route, users may benefit from broader liquidity access, competitive quotes, gas-abstracted execution and protection against adverse MEV, including front-running and sandwich attacks.

Limit-order functionality powered by 1inch allows users to set a target price and order expiry without continuously monitoring the market. Orders are cryptographically signed and remain offchain until filled. Market swaps and limit orders are available through the same wallet interface, providing a more consistent experience across immediate and target-price execution.

The upgrade also unlocks more flexible execution for eligible tokenized assets referencing stocks, ETFs and other supported RWAs, giving users expanded access to onchain markets and additional trading routes, subject to issuer requirements, user eligibility, network support, market availability and liquidity conditions.

By combining multichain access, broader market coverage and more flexible execution, KuCoin Web3 Wallet continues to evolve as an all-in-one self-custodial platform connecting users to crypto-native and TradFi-linked onchain opportunities.

About KuCoin Web3 Wallet

KuCoin Web3 Wallet is a self-custodial, multichain wallet and onchain access platform built for trading, market discovery and asset management. It brings together cross-chain swaps, wallet-native perpetual trading, supported tokenized real-world assets, Smart Money insights, and DApps within one connected experience. By integrating liquidity, execution and discovery tools directly into the wallet, KuCoin Web3 Wallet helps users move from market insight to onchain action while retaining control of their assets and private keys. With access to over 1,000 DApps and a dedicated airdrop hub featuring trending and newly listed tokens, KuCoin Web3 Wallet provides unified access to crypto-native and TradFi-linked onchain markets.

Learn more: X | Telegram | Instagram

Disclaimer

The information is for corporate PR purposes only and does not constitute endorsement or investment advice.

SOURCE KuCoin

Share this article

Acer's compact desktop design—Acer SFF RTX Spark—brings up to 1 petaflop of compute for powering agentic AI locally

Editor's Summary

- During the next@Acer global press conference on September 2, Acer showcased its Acer SFF RTX Spark design for a compact, ultra-efficient desktop powered by the NVIDIA RTX Spark superchip and purpose-built for the age of personal AI agents.

- It features up to a 6,144-core Blackwell RTX GPU, up to a 20-core NVIDIA Grace CPU, up to 1 petaflop of AI compute, and up to 128 GB of unified memory, paired with NVIDIA's full-stack AI platform and full suite of RTX technologies to accelerate AI innovation at the edge.

BERLIN, Sept. 2, 2026 /PRNewswire/ -- Acer showcased the Acer SFF RTX Spark design for a compact desktop powered by the NVIDIA RTX Spark superchip at Acer's next@Acer global press conference on September 2 during IFA 2026.

NVIDIA RTX Spark redefines personal computing, combining personal agents, advanced content creation and high-performance gaming in a new platform engineered from the ground up for the next wave of Windows PC experiences. Designed for creators, AI developers and gamers, NVIDIA RTX Spark brings NVIDIA's full-stack AI platform and full suite of RTX technologies to compact desktops.

Powered by NVIDIA RTX Spark at its core, the Acer SFF RTX Spark offers major compute power in a space-saving footprint for tapping into agentic AI running locally. The design is built to deliver up to 1 petaflop of AI performance and up to 128 GB of high-speed unified memory, delivering a combination of compute and data privacy.

Availability of RTX Spark™ devices from Acer will be announced at a future date.

About Acer

Founded in 1976, Acer is one of the world's top technology companies with a presence in more than 160 countries. The company continues to evolve by embracing innovation across its offerings, which include computers and displays, while branching out to new businesses. Acer is also committed to sustainable growth, exploring new opportunities that align with its environmental and social responsibilities. The Acer Group employs nearly 12,000 employees that contribute to the research, design, marketing, sales and support of products, solutions, and services that break barriers between people and technology. Visit www.acer.com for more information.

© 2026 Acer Inc. All rights reserved. Acer and the Acer logo are registered trademarks of Acer Inc. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners. All offers subject to change without notice or obligation and may not be available through all sales channels. Prices listed are manufacturer suggested retail prices and may vary by location. Applicable sales tax extra.

SOURCE Acer

Share this article

Editor's Summary

- Powered by an Intel Core Ultra X7 processor 358H and Intel Arc B390 graphics, the new Acer Veriton RI110 delivers high-performance, local AI computing for design, inference, and content creation, with support for AI models of up to 120 billion parameters.

- The device enables users to download and deploy their preferred agentic AI solution, including the new Acer Qubi Claw.

- OCuLink connectivity delivers up to 64 Gbps bandwidth for desktop-class GPU and storage expansion in a compact design.

BERLIN, Sept. 2, 2026 /PRNewswire/ -- Acer today announced the Acer Veriton RI110 AI Mini Workstation (VRI110), a compact yet powerful device engineered for organizations looking to accelerate AI innovation without compromising space, performance, or security. Powered by an Intel Core Ultra X7 processor 358H and Windows 11 Pro, the system delivers high-performance AI computing to expedite AI-assisted content creation, inference, design, and everyday productivity. Designed for modern AI workflows, the Veriton RI110 delivers the scalability and intelligence organizations require to balance local and cloud resources with the performance professionals expect.

Performance for Advanced AI Workflows

Built to support up to 120 billion parameter AI models, the Acer Veriton RI110 pairs an Intel Core Ultra X7 processor 358H with Intel Arc B390 graphics to deliver responsive performance across content creation, development, and AI-powered applications[1]. Complemented by up to 96 GB of LPDDR5X memory and up to 4 TB of PCIe Gen 4 SSD storage, the system enables fast multitasking and effective handling of complex datasets, models, and creative projects.

As a Copilot+ PC on Windows 11 Pro, Veriton RI110 also provides intelligent AI tools that help streamline everyday tasks and boost productivity[2]. From assisting with content creation to enhancing collaboration and workflow efficiency, it helps professionals accomplish more in less time and to focus on higher-value work.

Unleashing Hybrid Agentic AI

The Veriton RI110 comes equipped to tap into the full potential of hybrid agentic AI, supporting sandbox environments for privacy and security. The device aims to maximize choice for users, enabling them to download and deploy their preferred AI agents, including the new Acer Qubi Claw.

For automating everyday tasks, Acer Qubi Claw is Acer's handy agentic AI solution that can run local workflows in an isolated sandbox environment for maintaining data security. Coming with one-click installation, quick and easy setup, and ready-to-use AI skills, it helps AI models reason, plan, and act to automate tasks while protecting sensitive data. With the ability to schedule tasks autonomously or as needed, its initial skills include conducting in-depth research online, recommending travel itineraries and schedules, and capturing and translating audio into text notes. Acer Qubi Claw will continue to expand support for compatible AI models, skills, and channels.

OCuLink Connectivity for Unlocking Greater Performance

Further enhancing scalability, the Acer Veriton RI110 features OCuLink connectivity for high-performance expansion for AI computing, machine learning, 3D rendering, content creation, and professional workstation applications. The dedicated PCIe 4.0 x4 interface enables direct connections to external GPUs and high-speed NVMe storage, delivering up to 64 Gbps of bandwidth. Unlike traditional connections that add extra processing steps, OCuLink provides a faster, more efficient link to external devices, resulting in lower latency and improved performance.

The Veriton RI110 also delivers versatile connectivity for AI, creative, and business workflows, with a wide range of high-speed ports, display outputs, and expansion options to support evolving workplace needs. Wi‑Fi 7 and Bluetooth® 5.4 provide fast, reliable connectivity, and fingerprint authentication helps safeguard sensitive information and simplify secure sign-ins.

Availability

The Acer Veriton RI110 AI Mini Workstation will be available in North America in Q4'2026 and in EMEA in Q1'2027.

Exact specifications, prices, and availability will vary by region. To learn more about availability, product specifications, and prices in specific markets, please contact your nearest Acer office via www.acer.com.

Specifications

About Acer

Founded in 1976, Acer is one of the world's top technology companies with a presence in more than 160 countries. The company continues to evolve by embracing innovation across its offerings, which include computers and displays, while branching out to new businesses. Acer is also committed to sustainable growth, exploring new opportunities that align with its environmental and social responsibilities. The Acer Group employs nearly 12,000 employees that contribute to the research, design, marketing, sales and support of products, solutions, and services that break barriers between people and technology. Visit www.acer.com for more information.

© 2026 Acer Inc. All rights reserved. Acer and the Acer logo are registered trademarks of Acer Inc. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners. All offers subject to change without notice or obligation and may not be available through all sales channels. Prices listed are manufacturer suggested retail prices and may vary by location. Applicable sales tax extra.

© Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries.

SOURCE Acer

Share this article